Haemonetics Corporation $HAE Shares Bought by Hsbc Holdings PLC

Hsbc Holdings PLC boosted its stake in shares of Haemonetics Corporation (NYSE:HAE) by 239.6% during the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 37,256 shares of the medical instruments supplier’s stock after purchasing an additional 26,284 shares during the period. Hsbc Holdings PLC’s holdings in Haemonetics were worth $2,097,000 at the end of the most recent reporting period.

Other hedge funds have also bought and sold shares of the company. Kemnay Advisory Services Inc. purchased a new position in shares of Haemonetics in the fourth quarter worth $26,000. Leonteq Securities AG purchased a new stake in shares of Haemonetics during the fourth quarter valued at $30,000. EverSource Wealth Advisors LLC grew its holdings in shares of Haemonetics by 2,640.0% during the second quarter. EverSource Wealth Advisors LLC now owns 411 shares of the medical instruments supplier’s stock valued at $31,000 after buying an additional 396 shares during the last quarter. Kestra Advisory Services LLC purchased a new stake in shares of Haemonetics during the fourth quarter valued at $34,000. Finally, Bayforest Capital Ltd acquired a new position in shares of Haemonetics in the 4th quarter valued at $40,000. Institutional investors and hedge funds own 99.67% of the company’s stock.

Haemonetics Trading Down 0.3%

NYSE HAE opened at $78.56 on Monday. Haemonetics Corporation has a 1 year low of $47.31 and a 1 year high of $87.32. The company has a debt-to-equity ratio of 1.53, a current ratio of 2.95 and a quick ratio of 1.87. The company has a market capitalization of $3.57 billion, a PE ratio of 38.89, a P/E/G ratio of 1.59 and a beta of 0.52. The company has a fifty day moving average of $72.75 and a 200 day moving average of $66.06.

Haemonetics (NYSE:HAE) last announced its quarterly earnings results on Thursday, May 7th. The medical instruments supplier reported $1.29 earnings per share for the quarter, topping the consensus estimate of $1.28 by $0.01. The company had revenue of $346.35 million for the quarter, compared to the consensus estimate of $336.83 million. Haemonetics had a return on equity of 27.30% and a net margin of 7.29%.The firm’s revenue for the quarter was up 4.8% compared to the same quarter last year. During the same period last year, the firm earned $1.24 EPS. Haemonetics has set its FY 2027 guidance at 5.258-5.307 EPS. Research analysts forecast that Haemonetics Corporation will post 5.21 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of analysts have commented on the company. Mizuho lifted their price target on Haemonetics from $85.00 to $90.00 and gave the stock an “outperform” rating in a research report on Wednesday, July 15th. Barrington Research cut their price objective on Haemonetics from $94.00 to $89.00 and set an “outperform” rating on the stock in a report on Tuesday, May 12th. Weiss Ratings upgraded Haemonetics from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Thursday, June 25th. Citigroup reaffirmed a “neutral” rating on shares of Haemonetics in a report on Wednesday, July 8th. Finally, Bank of America upgraded Haemonetics from a “neutral” rating to a “buy” rating and upped their target price for the company from $72.00 to $80.00 in a research report on Friday, May 22nd. One research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating and four have issued a Hold rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $78.89.

Haemonetics Company Profile

Haemonetics Corporation is a global provider of blood management solutions that support the collection, processing and transfusion of blood and blood products. The company’s offerings are designed to enhance patient safety and operational efficiency for blood centers, hospitals and plasma collection facilities. Haemonetics serves healthcare providers worldwide by delivering integrated systems, software and consumables that address critical needs throughout the continuum of blood management.

The company’s product portfolio includes automated apheresis and plasma collection systems, surgical blood salvage and coagulation monitoring devices, and pathogen reduction technologies.